Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 11 2024
0mins
Should l Buy ILMN?
Source: NASDAQ.COM
Invesco Biotechnology & Genome ETF Overview: Launched in 2005, the Invesco Biotechnology & Genome ETF (PBE) focuses on the Health Care sector, utilizing a smart beta strategy to potentially outperform traditional market cap weighted ETFs. It has approximately $263.21 million in assets and an expense ratio of 0.58%.
Performance and Alternatives: PBE has shown a gain of about 15.99% over the past year, but it carries higher risk with a beta of 0.80. Investors may also consider lower-cost alternatives like the iShares Biotechnology ETF (IBB) and SPDR S&P Biotech ETF (XBI), which have larger asset bases and lower expense ratios.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ILMN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ILMN
Wall Street analysts forecast ILMN stock price to rise
13 Analyst Rating
4 Buy
6 Hold
3 Sell
Hold
Current: 114.440
Low
40.50
Averages
124.12
High
195.00
Current: 114.440
Low
40.50
Averages
124.12
High
195.00
About ILMN
Illumina, Inc. is engaged in providing sequencing-and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets, enabling the adoption of genomic solutions in research and clinical settings. Its DNA sequencing technology is based on its reversible terminator-based sequencing chemistry, referred to as sequencing by synthesis biochemistry. Its BeadArray technology combines microscopic beads and a substrate in a manufacturing process to produce arrays that can perform many assays simultaneously. Its sequencing applications include whole-genome sequencing kits, which sequence entire genomes of any size and complexity, and targeted resequencing kits, which can sequence exomes, specific genes, RNA or other genomic regions of interest. Its customers include genomic research centers, academic institutions, government laboratories, hospitals, pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and others.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Genomics Advancement: Illumina secures U.S. Medicare reimbursement for its TruSight™ Oncology Comprehensive test, expected to significantly enhance the generation of clinically relevant genomic data, thereby advancing routine genomic profiling in cancer care.
- Liquid Biopsy Expansion: Guardant Health expands the availability of its Shield™ colorectal cancer screening test to U.S. military personnel and their families, enhancing the foundational data generation for precision medicine through ctDNA analysis.
- Drug Discovery Innovation: Recursion Pharmaceuticals leverages AI and machine learning to accelerate drug discovery, emphasizing platform scalability to reduce development time and costs, while attracting institutional interest from firms like ARK Investment Management.
- Spider Silk Production Plan: Kraig Biocraft Laboratories plans large-scale deployment of its transgenic silkworm platform in 2026, aiming to achieve a production capacity of 10 metric tons of recombinant spider silk per month by May, potentially opening new markets for high-performance materials.
See More
- Dow Hits Record High: The Dow Jones Industrial Average surged 2.47% to reach an all-time high, reflecting market optimism about economic recovery, particularly amid strong rebounds in tech and chipmaker stocks.
- Consumer Confidence Rises: The University of Michigan's consumer sentiment index unexpectedly increased to 57.3, surpassing expectations of 55.0, indicating enhanced consumer confidence that could drive future spending.
- Bitcoin Rebounds: Bitcoin surged over 11% from a 1.25-year low, lifting cryptocurrency-exposed stocks and signaling renewed investor interest and confidence in crypto assets.
- Strong Corporate Earnings: Over 79% of S&P 500 companies exceeded earnings expectations, with S&P earnings growth projected at 8.4% for Q4, providing robust support for the market and indicating ongoing improvement in corporate profitability.
See More
- Market Performance: The S&P 500 Index rose by 1.10%, and the Dow Jones Industrial Average increased by 1.60%, reaching an all-time high, reflecting positive market sentiment driven by strong tech earnings results.
- Tech Stock Recovery: Gen Digital and Roblox surged over 7% and 9%, respectively, after forecasting full-year adjusted EPS and bookings above consensus, indicating a robust recovery in the tech sector that may attract more investment.
- Consumer Confidence Boost: The University of Michigan's consumer sentiment index unexpectedly rose to 57.3, a six-month high, surpassing expectations of 55.0, reflecting optimistic consumer sentiment about the economic outlook, which supports further market gains.
- Inflation Expectations Shift: While short-term inflation expectations fell, long-term expectations ticked up slightly, indicating market concerns regarding the Fed's monetary policy, which could influence future investment decisions and market volatility.
See More
- Tech Stock Rebound: The S&P 500 rose by 1.20% and the Dow Jones Industrial Average surged by 1.48%, reaching an all-time high, driven by better-than-expected tech earnings that boosted investor confidence in the sector's recovery.
- Bitcoin Recovery: Bitcoin rebounded over 7% from a 1.25-year low, lifting cryptocurrency-exposed stocks and alleviating concerns about liquidity in the crypto market, indicating renewed investor interest in digital assets.
- Amazon Investment Concerns: Amazon's announcement of a $200 billion investment in data centers, chips, and other equipment led to a more than 9% drop in its stock, raising doubts about the long-term returns of its AI investments and potentially impacting future investor confidence.
- Earnings Season Insights: With 79% of S&P 500 companies exceeding expectations and Q4 earnings projected to grow by 8.4%, this indicates strong corporate profitability, which may provide ongoing support for the market despite economic uncertainties.
See More
- Market Capitalization Surge: Nvidia became a $1 trillion company in 2023 and briefly surpassed $5 trillion in late 2025, highlighting its robust growth potential in the AI hardware sector and attracting significant attention from various enterprises.
- Significant Revenue Growth: In Q3 of fiscal 2026, Nvidia achieved a 62% year-over-year growth rate, with quarterly revenue exceeding $57 billion and operating income soaring 65% to $36 billion, demonstrating its strong competitive position in the market.
- Strong Debt Management: The company reduced its long-term debt by 4.7% in the same quarter, holding total debt of $10.8 billion against a net cash position of $11.49 billion, with cash reserves growing 26% year-over-year, indicating solid financial health.
- Robust Profitability: Nvidia's gross margin stands at 70%, with operating and net margins at 58% and 53% respectively, reflecting its leadership in the AI hardware market and sustained profitability, making it a compelling option for investors despite competitive pressures.
See More
- Significant Revenue Growth: Nvidia reported a 62% year-over-year revenue increase in Q3 of fiscal 2026, reaching $57 billion, reflecting strong demand in the AI hardware market and solidifying its leadership position.
- Enhanced Profitability: Operating income surged 65% to $36 billion, with diluted earnings per share rising 67%, indicating an efficient profit model while maintaining cost control, which boosts investor confidence.
- Robust Cash Flow: The company's free cash flow grew 31.5% year-over-year, and operating free cash flow increased by 34.7%, alongside a 26% year-over-year growth in cash holdings, providing financial flexibility for future investments and R&D.
- Expanding Market Share: Despite challenges from competitors like OpenAI, Nvidia remains the preferred supplier for AI hardware, and its full-stack AI hardware product line enhances its competitive edge, positioning the company to continue leading the industry.
See More








